1. Home
  2. ALLO vs BWMX Comparison

ALLO vs BWMX Comparison

Compare ALLO & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • BWMX
  • Stock Information
  • Founded
  • ALLO 2017
  • BWMX 1995
  • Country
  • ALLO United States
  • BWMX Mexico
  • Employees
  • ALLO N/A
  • BWMX N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • BWMX Catalog/Specialty Distribution
  • Sector
  • ALLO Health Care
  • BWMX Consumer Discretionary
  • Exchange
  • ALLO Nasdaq
  • BWMX Nasdaq
  • Market Cap
  • ALLO 677.5M
  • BWMX 553.8M
  • IPO Year
  • ALLO 2018
  • BWMX N/A
  • Fundamental
  • Price
  • ALLO $2.27
  • BWMX $12.06
  • Analyst Decision
  • ALLO Buy
  • BWMX Strong Buy
  • Analyst Count
  • ALLO 12
  • BWMX 1
  • Target Price
  • ALLO $10.06
  • BWMX $22.50
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • BWMX 27.9K
  • Earning Date
  • ALLO 11-07-2024
  • BWMX 10-24-2024
  • Dividend Yield
  • ALLO N/A
  • BWMX 11.20%
  • EPS Growth
  • ALLO N/A
  • BWMX N/A
  • EPS
  • ALLO N/A
  • BWMX 1.21
  • Revenue
  • ALLO $43,000.00
  • BWMX $700,821,742.00
  • Revenue This Year
  • ALLO N/A
  • BWMX $9.30
  • Revenue Next Year
  • ALLO $5,902.96
  • BWMX $6.59
  • P/E Ratio
  • ALLO N/A
  • BWMX $9.94
  • Revenue Growth
  • ALLO 26.47
  • BWMX 6.88
  • 52 Week Low
  • ALLO $2.01
  • BWMX $11.73
  • 52 Week High
  • ALLO $5.78
  • BWMX $21.28
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.00
  • BWMX 39.76
  • Support Level
  • ALLO $2.95
  • BWMX $12.00
  • Resistance Level
  • ALLO $3.36
  • BWMX $12.81
  • Average True Range (ATR)
  • ALLO 0.26
  • BWMX 0.47
  • MACD
  • ALLO -0.06
  • BWMX -0.05
  • Stochastic Oscillator
  • ALLO 0.91
  • BWMX 4.24

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About BWMX Betterware de Mexico S.A.P.I. de C.V.

Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.

Share on Social Networks: